Clinical trials: Nephrogenic Systemic Fibrosis
Nephrogenic Fibrosing Dermopathy
Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging
The purpose of this study is to evaluate the safety of linear and macrocyclic gadolinium-based contrast agents for patients with mild to moderate renal insufficiency.
- Trial name
- NCT04776187
- Testing
- Gadodiamide, Gadoteric Acid Meglumine Salt
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The Central Hospital of Lishui City
Fibrosis, Renal Impairment
Safety of Gadovist in Renally Impaired Patients
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate.
- Trial name
- GRIP (NCT00828737)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 70 sites in Australia, Austria and 8 more
- Volunteers
- 927 people
- Sponsor
- Bayer
Nephrogenic Systemic Fibrosis, Renal Failure
Nephrogenic Systemic Fibrosis With Gadollinum
Recently there is increasing reports of NEPHROGENIIC SYSTEMIC FIBROSIS(NSF) in patients with severe renal failure mainly in patients under dialysis in whom gadollinum is being used.
- Trial name
- NSF (NCT01359345)
- Testing
- gadollinum
- Where
- Iran
- Volunteers
- 200 people
- Sponsor
- Imam Khomeini Hospital
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Nephrogenic Systemic Fibrosis
Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.
- Trial name
- NCT01135316
- Testing
- Ablavar
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Lantheus Medical Imaging
Renal Insufficiency
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not…
- Trial name
- NCT00773409
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- Bracco Diagnostics, Inc
Chronic Kidney Disease, Renal Insufficiency
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI.
- Trial name
- NCT00908310
- Testing
- Omniscan
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- GE Healthcare
Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy
Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
The primary objective of this study is to determine any causative or associated factors for the development of Nephrogenic Systemic Fibrosis (NSF), Nephrogenic Fibrosing Dermopathy (NFD), or related diagnosis.
- Trial name
- NSF (NCT01014754)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Contrast Media
Primovist / Eovist in Renally Impaired Patients
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Primovist/Eovist, will be asked to participate.
- Trial name
- PERI (NCT00908596)
- Testing
- Gadoxetic acid disodium (Primovist, BAY86-4873)
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 357 people
- Sponsor
- Bayer
Nephrogenic Systemic Fibrosis
Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis
The Primary Aim of this study is to validate a questionnaire as a screening tool to identify subjects with symptoms suggestive of nephrogenic systemic fibrosis (NSF).
- Trial name
- NCT00869479
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis
Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
The purpose of this study is to evaluate the pathophysiology of nephrogenic fibrosing dermopathy (NFD)/nephrogenic systemic fibrosis (NSF).
- Trial name
- NFD (NCT01078987)
- Testing
- Plasmapheresis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Nephrogenic Systemic Fibrosis
Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
The purpose of this study is to determine the efficacy of imatinib mesylate in reducing cutaneous thickening and tethering in patients with nephrogenic systemic fibrosis (NSF).
- Trial name
- GENESYF (NCT00677092)
- Testing
- Imatinib mesylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Nephrogenic Systemic Fibrosis, Renal Insufficiency
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
The objective of this study is to prospectively monitor the incidence of adverse drug reactions, specifically NSF during routine use of gadoversetamide in a large number of patients with moderate renal insufficiency (eGFR 30-59)…
- Trial name
- SHERLOC (NCT00811863)
- Where
- United States
- Sponsor
- Guerbet
Renal Insufficiency
Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
The objective of this long-term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1 - patients with moderate chronic kidney disease eGFR 30 to 59 and Cohort 2 - patients with severe chronic kidney…
- Trial name
- NCT00600951
- Where
- United States
- Volunteers
- 366 people
- Sponsor
- Bracco Diagnostics, Inc
Nephrogenic Systemic Fibrosis
Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec
The investigators will study the effect of imatinib mesylate (Glivec) in treatment of moderate to severe nephrogenic systemic fibrosis (NSF). So far there is no evidence of adequately effective treatment options of NSF.
- Trial name
- NSF (NCT00981942)
- Testing
- Imatinib mesylate (Glivec)
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Renal Insufficiency
Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
The objective of this long term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1- patients with moderate chronic kidney disease eGFR 30-59 and Cohort 2- patients with severe chronic kidney disease…
- Trial name
- NCT00600834
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Bracco Diagnostics, Inc
Fibrosis, Kidney Failure
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled…
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Trial name
- NCT00744939
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- Bayer